Postrefractive surgery dry eye

Current Opinion in Ophthalmology

Volumn 19, Issue 4, 2008, Pages 335-341

  Quinto, Guilherme G ^a   Camacho, Walter ^a   Behrens, Ashley ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Dry eye syndrome; Laser in situ keratomileusis; Management; Ocular surface; Photorefractive keratectomy

Indexed keywords

ARTIFICIAL TEAR; CORTICOSTEROID; CYCLOSPORIN; DOXYCYCLINE; METHYLPREDNISOLONE; MITOMYCIN C;

CATARACTOGENESIS; CORNEA; CORNEA DISEASE; CORNEA HAZE; CORNEA SENSIBILITY; CORNEAL FLAP; DRY EYE; EYE INFLAMMATION; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HUMAN; KERATOMILEUSIS; LACRIMATION; LASER; MEIBOMIAN GLAND DYSFUNCTION; PHOTOREFRACTIVE KERATECTOMY; PRIORITY JOURNAL; REFRACTIVE SURGERY; REVIEW; SCHIRMER TEST; SEBACEOUS GLAND DISEASE; SENSORY NERVE; SERUM; SIDE EFFECT; SYMPTOM; TEAR FILM; TISSUE FLAP; TREATMENT OUTCOME; POSTOPERATIVE COMPLICATION;

DRY EYE SYNDROMES; HUMANS; POSTOPERATIVE COMPLICATIONS; REFRACTIVE SURGICAL PROCEDURES;

EID: 49849094912     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283009ef8     Document Type: Review

References (53)

1. Paiva CS, Chen Z, Koch DD, et al. The incidence and risk factors for developing dry eye after myopic LASIK. Am J Ophthalmol 2006; 141: 438-445.
2. Mian SI, Shtein RM, Nelson A, Musch DC. Effect of hinge position on corneal sensation and dry eye after laser in situ keratomileusis using a femtosecond laser. J Cataract Refract Surg 2007; 33:1190-1194.
3. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25:900-907.
4. Berry S, Mangione CM, Lindblad AS, McDonnell PJ. Development of the national eye institute refractive error correction quality of life questionnaire: focus groups. Ophthalmology 2003; 110:2285-2291.
5. Wilson SE. Laser in situ keratomileusis-induced (presumed) neurotrophic epitheliopathy. Ophthalmology 2001; 108:1082-1087.
6. Wilson SE, Stulting RD. Agreement of physician treatment practices with the International Task Force guidelines for diagnosis and treatment of dry eye disease. Cornea 2007; 26:284-289.
7. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:75-92.
8. Ang RT, Dartt DA, Tsubota K. Dry eye after refractive surgery. Curr Opin Ophthalmol 2001; 12:318-322.
9. Lemp MA. Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes. CLAO J 1995; 21:221-232.
10. Tseng SC, Tsubota K. Important concepts for treating ocular surface and tear disorders. Am J Ophthalmol 1997; 124:825-835.
11. Toda I. LASIK and dry eye. Compr Ophthalmol Update 2007; 8:79-85.
12. VitaleS, Goodman LA, Reed GF, et al. Comparison of the NEI-VFQand OSDI questionnaires in patients with Sjogren's syndrome-related dry eye. Health Qual Life Outcomes 2004; 2:44.
13. Schiffman RM, Walt JG, Jacobsen F, et al. Utility assessment among patients with dry eye disease. Ophthalmology 2003; 110:141 2-1419.
14. Lee HK, Lee KS, Kim HC, et al. Nerve growth factor concentration and implications in photorefractive keratectomy vs laser in situ keratomileusis. Am J Ophthalmol 2005; 139:965-971.
15. Solomon R, Donnenfeld ED, Perry HD. The effects of LASIK on the ocular surface. Ocul Surf 2004; 2:34-44.
16. Polunin GS, Kourenkov VV, Makarov IA, Polunina EG. The corneal barrier function in myopic eyes after laser in situ keratomileusis and after photorefractive keratectomy in eyes with haze formation. J Refract Surg 1999; 15: 221-224.
17. Yu EYW, Leung A, Rao S, Lam DSC. Effect of laser in situ keratomileusis in tear stability. Ophthalmology 2000; 107:2131-2135.
18. Lee JB, Ryu CH, Kim J, et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg 2000; 26:1326-1331.
19. Nejima R, Miyata K, TanabeT, et al. Corneal barrier function, tear film stability, and corneal sensation after photorefractive keratectomy and laser in situ keratomileusis. Am J Ophthalmol 2005; 139:64-71.
20. Komomi K, Chen LL, Tarko RS, et al. Preoperative characteristics and a potential mechanism of chronic dry eye after LASIK. Invest Ophthalmol Vis Sci 2008; 49:168-174.
21. Kanellopoulos AJ, Pallikaris IG, Donnenfeld ED, et al. Comparison of corneal sensation following photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg 1997; 23:34-38.
22. Perez-Santoja JJ, Sakla HF, Cardona C, et al. Corneal sensitivity after photorefractive keratectomy and laser in situ keratomileusis for low myopia. Am J Ophthalmol 1999; 127:497-504.
23. Matsui H, Kumano Y, Zushi I, et al. Corneal sensation after correction of myopia by photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg 2001; 27:370-373.
24. Donnenfeld ED, Solomon K, Perry HD, et al. The effect of hinge position on corneal sensation and dry eye after LASIK. Ophthalmology 2003; 110:1029-1030.
25. Campos M, Hertzog L, Garbus JJ, McDonnell PJ. Corneal sensitivity after photorefractive keratectomy. Am J Ophthalmol 1992; 114:51-54.
26. Chuck RS, Quiros PA, Perez AC, McDonnell PJ. Corneal sensation after laser in situ keratomileusis. J Cataract Refract Surg 2000; 26:337-339.
27. GambatoC, Ghirlando A, Moretto E, et al. Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology 2005; 28:208-218.
28. Bedei A, Marabotti A, Giannecchini I, et al. Photorefractive keratectomy in high myopic defect with or without intraoperative mitomycin C: 1-year results. Eur J Ophthalmol 2006; 16:229-234.
29. Kymionis GD, Tsiklis NS, Ginis H, Diakonis VF. Dry eye after photorefractive keratectomy with adjuvant mitomycin C. J Refract Surg 2006; 22:511-513.
30. Munoz G, Albarra'n-Diego C, Sakla HF, et al. Transient light-sensitivity syndrome after laser in situ keratomileusis with the femtosecond laser: incidence and prevention. J Cataract Refract Surg 2006; 32:2075-2079.
31. Rodriguez AE, Rodriguez-Prats JL, Hamdi IM, et al. Comparison of goblet cell density after femtosecond laser and mechanical microkeratome in LASIK. Invest Ophthalmol Vis Sci 2007; 48:2570-2575.
32. Albietz JM, Lenton LM, McLennan SG. Chronic dry eye and regression after laser in situ keratomileusis for myopia. J Cataract Refract Surg 2004; 30:675-684.
33. Toda I, Asano-Kato N, Hori-Komai Y, Tsubota K. Laser-assisted in situ keratomileusis for patients with dry eye. Arch Ophthalmol 2002; 120:1024-1028.
34. Toda I, Asano-Kato N, Hori-Komai Y, et al. Ocular surface treatment before laser in situ keratomileusis in patients with severe dry eye. J Refract Surg 2004; 20:270-275.
35. Noble BA, Loh RSK, MacLennan S, et al. Comparison of autologous serum eyedrops with conventional therapy in a randomized controlled crossover trial for ocular surface disease. Br J Ophthalmol 2004; 88:647-652.
36. Gipson IK, Hori Y, Argueso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf 2004; 2:131-148.
37. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 2000; 19:644-649.
38. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf 2004; 2:124-130.
39. Lemp MA. Evaluation and differential diagnosis of keratoconjunctivitis sicca. J Rheumatol (Suppl) 2000; 61:11-14.
40. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999; 106:811-816.
41. Perry HD, Donnenfeld ED. Topical 0.05% cyclosporine in the treatment of dry eye. Expert Opin Pharmacother 2004; 5:2099-2107.
42. Sall K, Stevenson OD, Mundorf TK, et al.Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107:631-639.
43. Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal antiinflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003; 136:593-602.
44. Salib GM, McDonald MB, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg 2006; 32:772-778.
45. Baxter SA, Laibson PR. Punctal plugs in the treatment of dry eyes. Ocul Surf 2004; 2:255-265.
46. Tai MC, Cosar CB, Cohen EJ, et al. The efficacy of silicone punctal plug therapy. Cornea 2002; 21:135-139.
47. Albietz JM, McLennan SG, Lenton LM. Ocular surface management of photorefractive keratectomy and laser in situ keratomileusis. J Refract Surg 2003; 19:636-644.
48. Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea 2007; 26:805-809.
49. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjögren's syndrome. Br J Ophthalmol 1999; 83:390-395.
50. Tsubota K, Higuchi A. Serum application for the treatment of ocular surface disorder. Int Ophthalmol Clin 2000; 40:113-122.
51. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea 2001; 20: 807-810.
52. Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31:579-583.
53. Noda-Tsuruya T, Asano-Kato N, Toda I, Tsubota K. Autologous serum eye drops for dry eye after LASIK. J Refract Surg 2006; 22:61-66.